Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, July 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Automotive Chassis Industry" - https://www.reportlinker.com/p05797965/?utm_source=GNW 8...
-
New York, NY, July 22, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Wireless Electric Vehicle Charging Systems Market By Service Type (Engine MRO, Avionics...
-
Pune, India., July 22, 2021 (GLOBE NEWSWIRE) -- Aircraft Turbine Fuel System Market: Key InsightsAccording to our new research study on “Aircraft Turbine Fuel System Market Forecast to 2028 –...
-
BOSTON and PETACH TIKVA, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of...
-
FOSTER CITY, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions powered by the Apache® Ignite® distributed database, today...
-
Winslow’s experience scaling enterprise software companies to accelerate company’s mission to disrupt the observability market BOSTON and HILVERSUM, The Netherlands, July 22, 2021 (GLOBE NEWSWIRE)...
-
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider, announced today that it will publish...
-
Dallas, July 22, 2021 (GLOBE NEWSWIRE) -- Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv® software, the end-to-end client experience platform for small businesses has expanded its...
-
– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2...
-
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta® (voxelotor) in Children with SCD Ages 4 to 11 Initiates Phase 3 Clinical Trials of Inclacumab and Enrolls First SCD Patient in...